Qudus Afolabi Akande

Dr. Qudus Afolabi Akande

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2024 in Bacteria
Verified
Journal Article
Open access
PDF file
OAOlalekan Chris Akinsulie
Olalekan Chris Akinsulie
Babatunde Ibrahim OlowuBabatunde Ibrahim Olowu
Babatunde Ibrahim Olowu
RARidwan Olamilekan Adesola
Ridwan Olamilekan Adesola
AAAdenike Adenaya
Adenike Adenaya
OBOlamilekan Gabriel Banwo
Olamilekan Gabriel Banwo
JAJesuferanmi Mary Akinsulie
Jesuferanmi Mary Akinsulie
Antiphospholipid syndrome (APS), also known as Hughes syndrome, is a systemic autoimmune disorder characterized by recurrent thrombosis and pregnancy complications, accompanied by the presence of antiphospholipid antibodies (aPLs). These antibodies target anionic phospholipids or protein–phospholipid complexes within cell membranes, contributing to the underlying mechanisms of the disease. Although anticoagulation therapy remains the cornerstone of APS management, it often fails to prevent complications, particularly in obstetric and thrombotic cases. As autoimmune diseases become increasingly linked to alterations in the gut microbiome, this study investigates the complex interaction between gut bacteria and immune modulation in APS. We explore how disruptions in the gut microbiome may influence the development of autoimmune conditions, with a specific focus on APS. By identifying key microorganisms potentially involved in this gut–immune axis, we aim to provide insights into novel preventive and control approaches. Future research should focus on harnessing the gut microbiome to develop more effective treatments that target both the immune system and microbial populations in APS patients.

3 October 2023 in Journal of Global Health Economics and Policy
Verified
Journal Article
Open access
PDF file
OAOlalekan Chris Akinsulie
Olalekan Chris Akinsulie
OOOluwagbemisola Oyin Olukogbe
Oluwagbemisola Oyin Olukogbe
IIIbrahim Idris
Ibrahim Idris
MJMelina Joshi
Melina Joshi
RWRhonda Williams
Rhonda Williams
QAQudus Afolabi Akande
Qudus Afolabi Akande
Background: Cholera and COVID-19 represent a dual burden on healthcare systems, especially in low-resource settings. Despite their significant impact, data on their co-occurrence and interaction remain unreliable. This is primarily due to limited and fragmented data availability, which affects our understanding of the relationship between these two diseases. This systematic review aims to address these gaps by summarizing the current state of knowledge and identifying specific data deficiencies. Methods: A comprehensive search was conducted on PubMed, Scopus, and Web of Science. The search was limited to studies published from January 2020 to December 2023. Specific search terms included “cholera and COVID-19 co-infection,” “cholera outbreaks during COVID-19,” and “impact of COVID-19 on cholera.” The Studies were selected based on predefined criteria, including relevance to the topic, quality of the data, and geographical scope. The Studies were selected based on predefined criteria, including relevance to the topic, quality of the data, and geographical scope. Results: A total of 18 studies were identified, encompassing a range of geographic locations and study designs. A meta-analysis revealed a strong positive correlation (95% confidence interval, CI=0.80, 0.99) between COVID-19 and cholera coinfection and comorbidity in Africa and Asia. Specifically, the correlation was observed between the frequency of cholera cases and the incidence of COVID-19, highlighting how the pandemic exacerbated cholera outbreaks in certain regions. Conclusions: The findings highlight the essential need for improved data collection and surveillance to better understand and manage the dual burden of cholera and COVID-19. The systematic review also highlights significant publication bias and data limitations, suggesting that future research should focus on addressing these gaps through enhanced data collection methods and rigorous analysis. Recommendations include developing targeted interventions to improve vaccination coverage and water, sanitation, and hygiene (WASH) practices, alongside strategies to counteract misinformation about vaccines. PROSPERO Registration ID: CRD42023485040

26 August 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
OAOlalekan Chris Akinsulie
Olalekan Chris Akinsulie
Babatunde Ibrahim OlowuBabatunde Ibrahim Olowu
Babatunde Ibrahim Olowu
RARidwan Olamilekan Adesola
Ridwan Olamilekan Adesola
AAAdenike Adenaya
Adenike Adenaya
OBOlamilekan Gabriel Banwo
Olamilekan Gabriel Banwo
JAJesuferanmi Mary Agbaje
Jesuferanmi Mary Agbaje
Antiphospholipid syndrome (APS) otherwise known as Hughes syndrome is a systemic autoimmune disease typically linked with characteristic features like thrombosis and pregnancy morbidity with the presence of antiphospholipid antibodies (aPLs). Although anticoagulation is the current flagship treatment for APS, there are reports indicating a considerable failure following this regimen in a significant number of obstetric APS and thrombotic APS cases. Antiphospholipid antibodies (aPLs) bind anionic phospholipids or protein-phospholipid complexes within the cell membrane. Here, we gave a general overview of the biology of APS and the human gut microbiome, our current understanding of the gut bacteria-immune axis in autoimmunity focus on the potential link to APS, highlighting the implicated microorganisms in this context, and proposing recommendations on future therapeutic development.

3 October 2023 in Journal of Global Health Economics and Policy
Verified
Journal Article
Open access
PDF file
OAOlalekan Chris Akinsulie
Olalekan Chris Akinsulie
OOOluwagbemisola Oyin Olukogbe
Oluwagbemisola Oyin Olukogbe
IIIbrahim Idris
Ibrahim Idris
MJMelina Joshi
Melina Joshi
RWRhonda Williams
Rhonda Williams
QAQudus Afolabi Akande
Qudus Afolabi Akande
Background: Cholera and COVID-19 represent a dual burden on healthcare systems, especially in low-resource settings. Despite their significant impact, data on their co-occurrence and interaction remain unreliable. This is primarily due to limited and fragmented data availability, which affects our understanding of the relationship between these two diseases. This systematic review aims to address these gaps by summarizing the current state of knowledge and identifying specific data deficiencies. Methods: A comprehensive search was conducted on PubMed, Scopus, and Web of Science. The search was limited to studies published from January 2020 to December 2023. Specific search terms included “cholera and COVID-19 co-infection,” “cholera outbreaks during COVID-19,” and “impact of COVID-19 on cholera.” The Studies were selected based on predefined criteria, including relevance to the topic, quality of the data, and geographical scope. The Studies were selected based on predefined criteria, including relevance to the topic, quality of the data, and geographical scope. Results: A total of 18 studies were identified, encompassing a range of geographic locations and study designs. A meta-analysis revealed a strong positive correlation (95% confidence interval, CI=0.80, 0.99) between COVID-19 and cholera coinfection and comorbidity in Africa and Asia. Specifically, the correlation was observed between the frequency of cholera cases and the incidence of COVID-19, highlighting how the pandemic exacerbated cholera outbreaks in certain regions. Conclusions: The findings highlight the essential need for improved data collection and surveillance to better understand and manage the dual burden of cholera and COVID-19. The systematic review also highlights significant publication bias and data limitations, suggesting that future research should focus on addressing these gaps through enhanced data collection methods and rigorous analysis. Recommendations include developing targeted interventions to improve vaccination coverage and water, sanitation, and hygiene (WASH) practices, alongside strategies to counteract misinformation about vaccines. PROSPERO Registration ID: CRD42023485040